

26th April, 2023

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: Initial Disclosure and Annual Disclosure pursuant to SEBI circular
SEBI/HO/DDHS/CIR/P/2018/144 dated 26-Nov-18**

Pursuant to SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26-Nov-18 pertaining to fund raising by issuance of Debt Securities by Large Entities read with SEBI Circular no. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/049 dated 31-Mar-23, we enclose herewith the initial disclosure in the prescribed format (**Annexure A**) and the annual disclosure in the prescribed format (**Annexure B2**) of the aforesaid SEBI Circular for the FY 2022-23.

Kindly take note on above.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI
COMPANY SECRETARY
Contact No: +91 79 26599000

Encl : A/a

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com

Initial Disclosure to be made by an entity identified as a Large Corporate

Sr. No.	Particulars	Details
1	Name of the Company	Torrent Pharmaceuticals Limited
2	CIN	L24230GJ1972PLC002126
3	Outstanding borrowing of Company as of March 31, 2023	Rs. 3368 Crores
4	Highest credit rating during the previous financial year with name of credit rating agency	Credit Rating given by ICRA: <ul style="list-style-type: none"> [ICRA] AA+ (Stable) for long term debt [ICRA] A1+ for short term papers Credit Rating given by India Rating: <ul style="list-style-type: none"> IND AA+ (Stable) for long term debt
5	Name of stock exchange [#] in which fine shall be paid, in case of shortfall in the required borrowing under the framework	National Stock Exchange of India Limited (NSE)

We confirm that we are a Large Corporate as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021.

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN
 MAHESHKU
 MAR TRIVEDI

Digitally signed by
 CHINTAN
 MAHESHKUMAR TRIVEDI
 Date: 2023.04.25 12:57:27
 +05'30'

Chintan M. Trivedi
 Company Secretary
 +91 79 26599000

SUDHIR MENON

Digitally signed by SUDHIR
 MENON
 Date: 2023.04.26 16:18:48 +05'30'

Sudhir Menon
 Chief Financial Officer
 +91 79 26599000

Date: 25th April, 2023

In terms para of 2.2(d) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,
 www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com

Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a LC

1. Name of the Company: Torrent Pharmaceuticals Limited
2. CIN: L24230GJ1972PLC002126
3. Report filed for FY: FY 2022-23
4. Details of the Current block (all figures in Rs. Crores)

Sr. No	Particulars	Details
1	3-year block period (Specify financial years)	FY 2022-23 FY 2023-24 FY 2024-25
2	Incremental borrowing done in FY 2022-23 (a)	1,395.00
3	Mandatory borrowing to be done through debt securities in FY 2022-23 (b) = (25% of a)	348.75
4	Actual borrowing done through debt securities in FY 2022-23 (c)	500.00
5	Shortfall in the borrowing through debt securities, if any, for FY 2021-22 carried forward to FY 2022-23. (d)	NIL
6	Quantum of (d), which has been met from (c) (e)	NA
7	Shortfall, if any, in the mandatory borrowing through debt securities for FY 2022-23 {after adjusting for any shortfall in borrowing for FY2021-22 which was carried forward to FY 2022-23} (f) = (b) - [(c) - (e)] {If the calculated value is zero or negative, write "nil"}	NIL

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore):

Sr.No	Particulars	Details
1	3-year block period (Specify financial years)	FY 2021-22 FY 2022-23 FY 2023-24
2	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}#	NA

(d) and (e) are the same as mentioned at sl. nos. 5 and 6 in the table given at point no. 4 of this annexure.

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN
 MAHESHKU
 MAR TRIVEDI
Digitally signed by CHINTAN MAHESHKUMAR TRIVEDI
 Date: 2023.04.25 12:58:17 +05'30'

Chintan M. Trivedi
 Company Secretary
 +91 79 26599000

Date: 25th April, 2023

SUDHIR MENON

Digitally signed by SUDHIR MENON
 Date: 2023.04.26 16:19:15 +05'30'

Sudhir Menon
 Chief Financial Officer
 +91 79 26599000

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,
 www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com